The hypothesis and design of the SHOCK trial have been previously published ... strongly recommended for both treatment arms. Standard clinical and hemodynamic criteria were applied for the ...

The Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial randomly assigned 302 patients with predominant left ventricular failure following an acute ...

Lead Drug Candidates, New Phase 2b Clinical Trial Data, Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF ...

Second Heart Assist announced today that it completed the third in a planned series of studies for its mechanical circulatory ...

The company’s lead indication area is cardiogenic shock (which is a severe form of heart failure) with istaroxime. Windtree recently commenced enrollment in its SEISMiC C trial in SCAI Stage C ...

WARRINGTON, PA — Windtree Therapeutics, Inc. has announced a new patent application for istaroxime derivatives, aimed at preventing or reducing the risk of acute myocardial arrhythmia. The filing ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...

The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...

Windtree Therapeutics (WINT) announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR ...

The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...